Cyclosporin and tacrolimus in clinical transplantation a comparative review

Clinical Immunotherapeutics

Volumn 5, Issue 5, 1996, Pages 351-373

  Jain, Ashokb ^a,b   Fung, John ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; TACROLIMUS;

DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERANCE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ORAL DRUG ADMINISTRATION; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0029886850     PISSN: 11727039     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03259333     Document Type: Article

References (210)

1. An illustrated history ol organ transplantation. The great adven lure of the century. Rueil-Malmaison (France): Laboratories SandoJ., 1992:45
2. Murray JE. Nobel Prize Lecture: first successful transplant in man. in: History ot transplantation: thirty-five recollections. Los Angeles: UCLA Tissue Typing Laboratory. 1991
3. L'nited Network lor Organ Sharing. UNOS update 1995: II i I i: 34-40
4. Schwanz R, Dameshek W. The effects of 6-mercaptopurine on homograft reactions. J Clin Invest 1960; 39: 952-8
5. Calne RY. Inhibition of the rejection of renal homografts in dogs by purine analogues. Transplant Bull 1961; 26: 65-81
6. Zukoski CF, Lee HM, Hume DM. The prolongation of functional survival of canine renal homografts by 6-mercaptopurine. Surg Forum 1960; 11: 470-2
7. Dammin GJ. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963; 268:1315-23
8. Billingham RE, Krohn PL, Medawar PB. Effect of locally applied cortisone acetate on survival of skin homografts in rabbits. BMJ 1951; 2: 1049-53
9. Morgan JA. The influence of cortisone on the survival of homografts of skin in the rabbit. Surgery 1951; 30: 506-15
10. Starzl TE, Marchioro TL, Waddel WR, et al. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance. Surg Gynecol Obstet 1963; 117: 385-95
11. Murray JE, Merrill JP, Harrison JH, et al. Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med 1963; 268 (24): 1315-23
12. Todo S, Tzakis A, Reyes J, et al. Intestinal transplantation at the University of Pittsburgh. Transplant Proc 1994; 26: 1409-10
13. Schreiber SL. Chemistry and biology of the immunophilins and their immunosuppressive ligands. Science 1991; 251: 283-7
14. Liu J, Farmer Jr JD, Lane WS, et al. Calcineurin is a common target of cyclosporine A and FKBP-FK506 complexes. Cell 1991;66:807-15
15. Fruman DA, Lkee CB, Bierer BE, et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyciosporine A. Proc Nail Acad Sei USA 1992; 89: 3686-90
16. Liu J, Albers MW, Wandles TJ, et al. Inhibition of T cell signalling by immunophilin-ligand complexes correlates with loss of calcineurin phosphatase activity. Biochemistry 1992: 31: 3896-901
17. Hess AD, Esa AN, Colombani PM. Mechanisms of action of cyclosporine: effect on cells of the immune system and on subcellular events in T cell activation. Transplant Proc 1988; 20 (Suppl. 2): 29-40
18. Wagner H. Cyclosporine A: mechanism of action. Transplant Proc 1983; 15:523-6
19. KinoT, Hatanaka H, Miyata S, et al. FK-506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK 506 in vitro. J Antibiot 1987; 40: 1256-65
20. Schreiber SL, Crabtree GR. The mechanisms of action of cyclosporine A and FK506. Immunol Today 1992; 13: 136
21. Thomson AW, Carroll PB, McCauly J, et al. FK 506: a novel immunosuppressant for treatment of autoimmune disease. Springer Semin Immunopathol 1993; 14: 323-44
22. Donatsch P, Abisch E, Hornberger M, et al. A radioimmunoasxay to measure cyclosporin A in plasma and serum samples. J Immunoassay 1981; 2: 19-32
23. Randal G, Jacobs P. Cyclosporin-A radioimmunoassay: a modified method for whole blood determination. Exp Hematol 1985; 13(9): 874-8
24. Jusko WJ, D'Ambrosio R. Monitoring FK506 concentration in plasma and whole blood. Transplant Proc 1991; 23 (6): 2732-5
25. Oka K, Hosoda K, Sakurai E, et al. Determination of cyclosporin A in the serum of kidney transplant patients by rapidflow fractionation and normal-phase high-performance liquid chromatography. J Chromatogr 1989; 490 ( 1 ): 145-54
26. Plebani M, Masiero M. Paleari CD, et al. High-performance liquid chromatography for cyclosporin measurement: comparison with radioimmunoassay. J Chromatogr 1989; 476: 93-8
27. SchroederTJ, Brunson ME, Pesée AJ, et al. Comparison of the clinical utility of the radioimmunoassay, high performance liquid chromatography and Tdx cyclosporine assays in outpatient renal transplant recipients. Transplantation 1989; 47: 262-6
28. Burckart GJ, Jain A, Diven W, et al. Cyclosporine measurement by FPIA, PcRIA and HPLC following liver transplantation. Transplant Proc 1990; 22: 1319-22
29. Yatscoff RW, Copeland KR, Farari CJ. Abbott Tdx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clin Chem 1990; 36: 1969-73
30. Gunson BK, Jones SR, Buckles J AC, et al. Liver transplantation in Birmingham. Use of cyclosporine clinical correlation with drug monitoring. Transplant Proc 1990; 22: 1312-8
31. Yatscoff RW, Rosano TO, Bowers LD. The clinical significance of cyclosporin metabolites. Clin Biochem 1991 ; 24 ( 1 ): 23-3S
32. Cadoff EM, Venkataramanan R, Krajack A, et al. Assay of FK506 in plasma. Transplant Proc 1990; 22 (1): 50-1
33. Jusko WJ, Piekoszewski W, Klintmalm OB, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57 (3): 281-90
34. Warty VJ, Zendehrouh P, Mehta S, et al. Practical aspects of FK506 analysis (Pittsburgh experience). Transplant Proc 1991; 23 (6): 2730-1
35. Zeevi A, Eiras G, Burckart G, et al. Bioassay of plasma specimens from liver transplant patients on FK506 immunosuppression. Transplant Proc 1990; 22 ( 1 ): 60-3
36. Zeevi A, Eiras G, Kautman C, et al. Correlation between bioassayed plasma levels of FK 506 and lymphocyte growth from liver transplant biopsies with histological evidence of rejection. Transplant Proc 1991 ; 23 ( 1 Pt 2): 1406-8
37. Grenier FC. Luczkiw J, Bergmann M, et al. A whole blood FK506 assay for IMx analyzer. Transplant Proc 1991 ; 23 (6): 2748-9
38. Warty VS. Zuckerman S, Venkataramanan R, et al. FK506 measurement: comparison of different analytical methods. Ther Drug Monit 1993; 15: 204-8
39. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (part I). Clin Pharmacokinet 1990; 19: 319-32
40. Yee GC. McGuire TR. Pharmacokinetic drug interactions with cyclosporin (part 2). Clin Pharmacokinet 1990; 19: 400-15
41. Butman SM. Wild JC. Nolan PE, et al. Prospective study of safety and financial benefit of ketoconazole as adjunct therapy to cyclosporine A after heart transplantation. J Heart Lung Transplant 1991; 10:351-8
42. Bourge RC, Kiklin JK, Nuftel DC. et al. Diltiazem-cyclosporine interaction in cardiac transplant patients: impact on cyclosporine dose and medication costs. Am J Med 1991 ; 90:402-3
43. Alishah I. Whitting PH. Omar A, et al. Effect of FK506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. Transplant Proc 1991; 23 (6): 2783-5
44. Moochlala SM, Lee EJD, Earnest L, et al. Inhibition of drug metabolism in rat and human liver microsomes by FK506 and cyclosporine. Transplant Proc 1991; 23 (6): 2786-8
45. Wood AJ, Maurer G, NiederbergerW. et al. Cyclosporine: pharmacokinetics, metabolism, and drug interactions. Transplant Proc 1983; 15:2409-12
46. Christians U, Braun F, Disian N, et al. High performance liquid chromatography mass spectromelry of FK506 and its metabolites in blood, bile and urine of liver grafted patients. Transplant Proc 1991; 23 (6): 2741-4
47. Venkataramanan R. Jain AB. Cadofl'E. el I. Pharmacokinetics of FK506: preclinical and clinical studies. Transplant Proc 1990: 22(1): 52-6
48. Venkataramanan R. Jain AB. Warty VW, et al. Pharmacokinetics of FK506 following oral administration. A comparison of FK506 and cyclosporine. Transplant Proc 1991 ; 23: 931 -3
49. Venkataramanan R, Jain AB. Warty VS, et al. Pharmacokinetics of FK506 in transplant patients. Transplant Proc 1991:23(6): 2736-40
50. Ptacheinski RJ. Venkataramanan R. Burckart GJ. Clinical pharmacokinelics of cyclosporin. Clin Pharmacokinet 1986: II: 107-32
51. Venkataramanan R. Swaminathan A. Prasad T. et al. Clinical phanriacokinetics of tacrolimtis. Clin Pharmacokinel 1995; 29 16): 404-30
52. Jain AB. Venkataramanan R. Cadoff E. et al. Effect of hepaticdysfunction and T-tube clamping on FK506 pharmacokinetics and trough concentrations. Transplant Proc 1990: 22 ( 1 ): 57-9
53. Mehta M. Venkataramanan R. Burckart GJ. et al. Effect of bile on cyclosporine absorption in liver transplant patients. Br J Clin'pharmacol 1988: 25: 579-84
54. Andrews W. Iwatsuki S. Shaw Jr BW. Cyclosporine monitoring in liver transplant patients |lctlerj. Transplantation 1985: 39 (3): 338
55. Mueller EA. Kallay Z. Kovarik JM. et al. Assessment ot glomerular filtration rate after multiple administration ot a new oral formulation of cyclosporine in clinically stable renal transplant patients. Transplant Proc 1995: 27 ( 1 ): 834-6
56. Trull AK. Tan KKC. Uttridgc J. et al. Cyclosporin absorption from microemulsion formulation in liver transplant recipients. Lancet 1993:341:433
57. Ahu-Elmagd K. Fung JJ. Alessiani M. et al. The effect of graft function on FK506 plasma levels, doses, and renal function: with particular reference to the liver. Transplantation 1991; 52(1): 71-7
58. S. Jain AB. Elias E, Gunson BK. et al. Is elimination of cyclosporine In bile dependent on liver graft function and biliary drainage ' Transplant Proc 1988; 20 (2 Suppl.): 516-22
59. Venkataramanan R, Starzl TE. Yang S. et al. Biliary excretion of cyclosporine. Transplant Proc 1981; 17 ( I ): 286
60. Zeevi A. Eiras G. Kaufman C. et al. Correlation between bioassayed plasma levels of FK506 and lymphocyte growth from liver transplantation biopsies with histological evidence of rejection. Transplant Proc 1991: 23: 1406-8
61. Winkler M. Wonigeit K. LJndre N. et al. Comparison of plasma vs whole blood as matrix for FK506 drug level monitoring. Transplant Proc 1995; 27 ( I ): 822-5
62. Ferguson RM. Sutherland DER. Simmons RL. et al. Ketocon azole. cyclosporine metabolism, and renal transplantation. Lancet l'982: II: 882-3
63. Freeman DJ. Laupacis A. Keown PA. et al. Evaluation of cyclo sporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol 1984; 18: 887-93
64. Ptacheinski RJ. Carpenter BJ. Burekart GJ. et al. Effect of ervthromycin on cyclosporine levels. N Engl J Med 1985; 3l'.3: 1416-7
65. Zeevi A. Venkatramanan R. Warty V. et al. In vitro assessment of FK506 immunosuppressive activity in transplant patients. Transplant Proc 1991: 23 (6): 2897-9
66. Mieles L. Venkataramanan R. Yokoyama I. et al. Interaction between FK506 and clotrima/ole in a liver transplant recipi eut. Transplantation 19y|:52(6>: 1086-7
67. Mane? R. Martin M. Raman D. et al. Flueonazole therapy in transplant recipients receiving FK506. Transplantation 1994: 57(10): 1521-3
68. Koneru B. Hartner C. Iwatsuki S. et al. Effect of dana/ol on cyclosporine pharmacokinetics. Transplantation 1988; 45 (5 ): moi
69. Jensen C. Jordan M, Shapiro R. et al. Interaction between tacrolimus and erythromycin. Lancet 1994: 344: 825
70. Shupiro R. Venkataramanan R. Warty VS. et al. FK 506 interaction with danazol. Lancet 199.1: 341: 1344-5
71. Starzl TF. Iwatsuki S. Van Thiel DH. et al. Evolution of liver transplantation. Hepatology 1982: 2: 614-36
72. Iwatsuki S. Starzl TE. Todo S. et al. Experience in 1,000 Iher transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc 1988: 20 Suppl. 1: 498-504
73. Pichlamyr R. Brofsch C. Neuhaus P. Report on 68 human or (hotopic liver transplantations with special reference to rejection phenomena. Transplant Proc 1983: 15: 127983
74. Gordon RD. Shaw Jr BW. Iwatsuki S. et al. Indications for liver transplantation in the cyclosporine era. Surg Clin North Am 1986:66: 541-56
75. Jamieson NV. Calne R. Rolles K. et al. Results and problems in pédiatrie liver transplantation in the Cambridge/Kings College Hospital series 1968-July 1986. Transplant Proe 1987: 19: 2447-8
76. Star/I TE. Todo S. Fung JJ. et al. FK506 lor liver, kidney, and pancreas transplantation. Lancet 1989:11: 1000-4
77. Fung JJ. Todo S, Jain AB, et al. Conversion of liver allograft recipients with cyclosporine related complications from cyclosporine to FK506. Transplant Proc 1990:22 (11: 6-12
78. Dcmetris AJ, Fung JJ. Todo S. et al. FK506 used as rescue therapy for human liver allograft recipients. Transplant Proc 1991; 23 (6): 3005-6
79. Demetris AJ. Fung JJ. Todo S. et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppresshe therapy: a clinicopathologic study of 96 patients. Transplantation 1992; 53 (2): 1056-62
80. l'S MulticenterFK5()6 Study Group. Prognostic factors for successful conversion from cyclosporine to FK506-based immunosuppresshe therapy for refractory rejection after liver transplantation. Transplant Proc 1993; 25: 641-3
81. D'Alessandro AM. Kalavoglu M. Pirsch JD. et al. FK506 rescue therapy for resistant rejection episodes in liver transplant recipients. Transplant Proc 1991; 23: 2987
82. Lewis WD, Jenkins RL. Burke PA. el al. FK506 rescue therapy m liver transplant recipients with drug-resistant rejection. Transplant Proc 1991:23: 1989
83. Shaw BW. Markin R. Stratta R, et al. FK506 for rescue treatment ol acute and chronic rejection in liver allograft recipients. Transplant Proc 1991: 23: 2994-5
84. Rueay P. Samuel D. Farges O. et al. FK506 as treatment of late acute rejection in liver transplant patients. Transplant Proc 1995: 27 II): I105-6
85. Jost U, Winkler M. Ringe B. et al. FK506 treatment of intractable rejection after liver transplantation. Transplant Proc 1993:25(4): 2686-7
86. McDiarmid SV. Klintmalm GB. Busuttil RW. FK506 conversion for intractable rejection of the Iher allografl. Transpl Int 1993:6(6): 305-12
87. Fung JJ. Todo S, T/akis A. et al. Conversion ol liver allografl recipients from cyclosporine to FK506 based immunosup pression: benefits and pitfalls. Transplant Proc 1991: 23: 14-21
88. Felser I, Wagner S, Depee J, et ai. Changes in quality of life following conversion from CyA to FK506 in orthotopic liver transplant patients. Transplant Proc 1991; 23 (6): 3032-4
89. Tzakis AG, Reyes J, Todo S, et al. Two-year experience with FK506 in pédiatrie patients. Transplant Proc 1993; 25 ( 1 Book 1): 619-21
90. Reding R, Wallemacq PE, Lamy ME, et al. Conversion from cyclosporine to FK506 for salvage of immunocompromised pédiatrie liver allografts: efficacy, toxicity and dose regimen in 23 children. Transplantation 1994; 57 (I): 93-100
91. Todo S, Fung JJ. Demetris AJ, et al. Early trials with FK506 as primary treatment in liver transplantation. Transplant Proc 1990:22(1): 13-16
92. TodoS, Fung JJ.Tzakis A.etal. 110 consecutive primary orthotopic liver transplantation under FK506 in adults. Transplant Proc 1991:23: 1399-402
93. Jain AB, Fung JJ, Todo S, et al. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK506. Transplant Proc 1991; 23: 931-3
94. Todo S, Fung JJ. Starzl TE, et al. Single center experience with primary orthotopic liver transplantation under FK506 immunosuppression. Ann Surg 1994; 220: 297-309
95. Fung JJ, Abu-Elmagd K, Jain AB, et al. A randomized trial of primary liver transplantation under immunosuppression with FK506 versus cyclosporine. Transplant Proc 1991; 23 (6): 2977-83
96. Fung JJ, Todo S, Abu-Elmagd K, et al. Randomized trial in primary liver transplantation under immunosuppression with FK506 or cyclosporine. Transplant Proc 1993; 25 ( 1 ): II30
97. Fung JJ, Eliasziw M, Todo S, et al. The Pittsburgh randomiJ.ed trial of tacrolimus vs cyclosporin for liver transplantation. J Am Coll Surg. In Press
98. European FK506 Multicentre Liver Study Group. Randomized trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423-4
99. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110-5
100. Starzl TE, Donner A, Eliasziw M, et al. Randomized trialomania?: the multicenter liver transplant trials. Lancet 1995; 346: 1346-50
101. Jain A, Fung JJ, Todo S, et al. Conversion from FK506 to cyclosporine due to FK506 toxicity following orthotopic liver transplantation [abstract]. American Society of Transplant Physicians 13th Annual Scientific Meeting; 1994 Chicago (IL): 2-36
102. TakayaS, BronstherO, TodoS. et al. Retransplantation of liver: a comparison of FK506 and cyclosporine treated patients. Transplant Proc 1991; 23 (6): 3026-8
103. McDiarmid SV, Busuttil RW, Ascher NL, et al. FK506 (tacro limus) compared with cyclosporin for primary immunosuppression after pédiatrie liver transplantation. Transplantation 1995; 59 (4): 530-6
104. Lake JR, Gorman KJ, Esuivel CO. et al. The impact of immunosuppressive regimens on the cost of liver transplantation results from the U.S. FK506 multicenter trial. Transplantation 1995:60(10): 1089-95
105. Calne RY, White DJ, Thiru S, et al. Cyclosporine A inpatients receiving renal allografts from cadaver donors. Lancet 1978; II: 1323-7
106. Calne RY, Rolles K. White DJG, et al. Cyclosporine A initially as the only immunosuppressant in 34 recipients of cadavericorgans: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979: II: I033-6
107. European Multicentre Trial Group. Cyclosporine in cadaveric renal transplantation. One year follow up of a multicentre trial. Lancet 1983; II: 986-9
108. Canadian Multicenter Transplant Study Group. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N Engl J Med 1983; 309: 809-15
109. European Multicentre Trial Group. Cyclosporine in cadaveric renal transplantation. Follow up at three years of a multicentre trial. Transplant Proc 1986: 18: 1229-33
110. Canadian Multicenter Transplant Study Group. A randomized clinical trial of cadaveric renal transplantation: analysis at three years. N Engl J Med 1986; 314: 1219-25
111. Calne RY. Cyclosporine in cadaveric renal transplantation: 5 year follow up of a mullicenter trial. Lancet 1987; II: 506-7
112. Jain AB. Buckles JAC, Adu D. et al. Long-term results of cyclosporine renal transplantation from a single center. Transplant Proc 1988; 20 (2 Suppl. 3): 82-5
113. Burke JE, Pirsch JD, Ramos EL, et al. Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 1994; 331 (6): 358-63
114. Montagnino G, Colturi C, Tarantino A, et al. The impact of azathioprine and cyclosporine on long-term function in kidney transplantation. Transplantation 1991; 51 (4): 772-6
115. Wrenshall LE. Matas AJ, Canafax DM, et al. An increased incidence of late acute rejection episodes in cadaver renal allograft recipients given azathioprine, cyclosporine, and prednisone. Transplantation 1990; 50: 233-7
116. Ponticelli C, Tarantino A, Montagnino G, et al. A randomized trial comparing triple-drug and double-drug therapy in renal transplantation. Transplantation 1988; 45: 913-8
117. Saloman D, Brunson M, Vansickler J, et al. A retrospective analysis of late renal graft function: correlation with mean cyclosporin levels and lack of evidence for chronic cyclosporin toxicity. Transplant Proc 1991; 23: 1018-9
118. Almond PS. Matas A, Gillingham K. et al. Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993; 55: 752-7
119. Dunn J, Golden D, Van Buren CT. et al. Causes of graft loss heyond two years in the cyclosporine era. Transplantation 1990; 49: 349-53
120. Lewis RM, Van Buren CT, Radovancevic B, et al. Impact of long-term cyclosporine immunosuppressive therapy on na live kidneys versus renal allografts: serial renal function in heart and kidney transplant recipients. J Heart Lung Transplant 10: 63-70
121. Lewis RM, Van Buren CT, Kerman RH, et al. A review of longterm cyclosporine use in renal transplantation. Clin Transpl 1990; 4: 313-20
122. Amend W, Soskin T. Vincenti F. et al. Long-term experience in primary cadaver renal transplants using cyclosporine. Clin Transpl 1990; 4: 341-6
123. Jordan ML, Shapiro R, Jensen CWB, et al. FK506 conversion of renal allografts failing cyclosporine immunosuppression. Transplant Proc 1991; 23 (6): 3078-81
124. Jordan ML. Shapiro R, Vivas ÇA, et al. FK506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression. Transplant Proc 1993; 25 ( 1 Book I): 6.38-40
125. Ciancio G, Roth D, Burke G, et al. Renal transplantation in anew immunosuppressive era. Transplant Proc 1995; 27 ( 1 ): 812-3
126. Starzl TE, Fung J, Jordan M, et al. Kidney transplantation under FK506. JAMA 1990; 264: 63-7
127. Ochiai T. Ishibashi M, Fukao K, et al. Japanese multicenter studies of FK506 in renal transplantation. Transplant Proc 1995; 27 (11:50-6
128. I2X. Ochiai T. Fukao K. Takahashi K. el a!., Japanese FK506 Study Group. Phase III study of FK506 in kidney transplantation. Transplant Proc 1995:~27 ( I ): 829-3.1
129. Wengerten K, Matas AJ. Tcllis VA. et al. Transplantation of pédiatrie donor kidneys to adult patients. Ann Surg 1986: 204: 172-5
130. Darras FS. Jordan ML. Shapiro R. Transplantation of pédiatrie en bloc kidneys under FK506 imimmosuppression. Transplant Proc 1991:23(6): 3089-90
131. Jensen CWB. Jordan ML. Schneek FX. et al. Pédiatrie renal transplantation under FK 506 immunosuppression. Transplant Proc 1991: 23 (61: 3075-7
132. Scamlehury VP. Shapiro R. Tzakis A. et al. Pédiatrie kidney transplantation at the University of Pittsburgh. Transplant Proc 1994: 26 ( I ): 46-7
133. Shapiro R. Jordan M. Scantlebury V. et al. FK506 in clinical kidney transplantation. Transplant Proe 1991 ; 23 (6): 3065 7
134. Demetris AJ. Banner B. Fling J. et al. Histopathology of human renal allograft rejection under FK506: a comparison with cyclosporine. Transplant Proe 1991: 23: 944-6
135. Shapiro R. Jordan ML. Scantlebury VP. et al. A prospective, randomized trial of FK506/prednisone vs FK506/a/alhioprine/prcdnisone in renal transplant patients. Transplant Proc 1995: 27(1): 814-7
136. Laskow DA. Vincenti F. Neylan J, et al. Phase II FK506 multicenter concentration control study: one-year follow-up. Transplant Proc 1995: 27 ( I ): X09-11
137. Over PL;. Stinson F.B. Jamieson SW. et al. Cyclosporine in car diac transplantation. A two and a half year follow up. Transplant Proc 1983: 15:2546
138. X. Hakim M, Spiegelhalter D. English T. et al. Cardiac transplantation with cyclosporine and steroids: medium and long term results. Transplant Proc 1988; 20 (Suppl. 3): 327-32
139. Kaye MP. The Registry of the International Society for Heart and Lune Transplantation: ninth official report. J Heart Lung Transplant 1992: 11:599-606
140. Kriett JM. Kaye MP. The Registry of the International Society for Heart and Lung Transplantation: eighth official report. J Heart Lung Transplant 1991: 10:491-8
141. Olivari MT. Antolick A. Ring WS. Arterial hypertension in heart transplant recipients treated with triple-drug immunosuppressive therapy. J Heart Transplant 1989; 8: 34-9
142. Barr ML, Sanche/ JA. Seche LA. et al. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation. Circulation 1990: 82 (Suppl. 4): 291-5
143. Armitage JM. Pricker FJ. Del Nido P. el al. A decade (19X21992) of pédiatrie cardiac transplantation and the impact of FK506 immunosuppression. J Thorac Cardiovasc Surg 1993: 105:464-72
144. Armitage JM. Kormos RL. Fung J. el al. The clinical trial of FK506 as primary and rescue iirimnnosuppression in adult cardiac transplantation. Transplant Proc 1992: 23 (6): 3054-7
145. Pham SM, Armitage JM. Kormos RL. et al. Rescue therapy with FK-506 in cardiac transplantation. Circulation 1993: 8S (4 Pi 2): 1-94
146. Armitage JM. Kormos RL. Morita S. et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg 1992:54: 205-11
147. Dew MA, Harris RC, Simmons RG. et al. Quality of-life ad\ anläge of FK 506 \s conventional immunosuppressive drug therapy in cardiac transplantation. Transplant Proc 1991: 23 (61: 3061-4
148. X. Burke CM. Theodore J. Baldwin JC. ei al. Twenty eight cases of human heart-lung transplantation. Lancet 19X6: I: 517-9
149. Griffith B P. Bando K. Armitage JM. el al. Lung transplantation at the University of Pittsburgh. In: Tera.saki PI. Cecka. editors. Clinieal transplantation. Los Angeles (CAl: UCLA Tissue Typing Laboratory 1992: 149-59
150. Griffith BP. Hardesty RL. Armitage JM. et al. Acute rejection of king allografts with various imiminosuppressive protocols. Ann Thorac Surg 1992: 54 (5): 846-51
151. Griffith BP, Bando K. Hardesty RL. et al. A prospective ran domiml trial of FK506 versus cyclosporine after human pulmonary transplantation. Transplantation 1994: 57: 848-56
152. Keenan RJ. Konishi H. Kavvai A. et al. Clinical trial ol tacrolimus versus cyclosporin in lung transplantation. Ann Thorac Surg 1995:60:580-5
153. Calne RY. White DJG. The use of cyclosporine A in clinical organ grafting. Ann Surg 1982: 196: 330-6
154. Hedman L. Frisk B, Brynger H, et al. Severe kidney graft rejection in combined kidney and pancreas transplantation. Transplant Proc 1987: 29 (5): 3911-2
155. Teraoka S. Baba/ono T. Koike T. et al. Effect of rescue therapy using FK 506 on relapsing rejection after combined pancreas and kidney transplantation. Transplant Proe 1995: 27 ( I I: 1335-9
156. Gruessner RWG. FK506 Pancreatic Transplant Cooperative Study Group. Multicentre analysis of first experience with FK506 lor induction and rescue therapy after pancreatic ( PA} transplantation (Tx) (abstract|. American Society of Transplant Surgeons' 2Lst Annual Scientific Meeting; 1995 May: Chicago (ID: 33. abstr. 1-2
157. Grant D. Wall W. Mimeaull R. et al. Successful small bowel/ liver transplantation. Lancet 1990:335(1): 181-4
158. Schroeder P. Goulel O. I,ear PA. Small bowel transplantation: European experience [letter]. Lancet 1990; 336: 110-1
159. Cirant DR. linmunosuppression for small bowel transplantation. ClinTranspl 1991:5(6111:563-7
160. Todo S. I>akis A. Reyes J. el al. Intestinal transplantation in humans under FK 506. Transplant Proc 1993; 25 ( I Book III: 1198-9
161. Todo S. Tzakis A. Abu-F.lmagd K. el al. Cadaveric small bow el and small bowel-liver transplantation in humans. Transplantation 1992:53 (2): 369-76
162. Todo S. Tzakis A. Rev es J. el al. Intestinal transplantation: 4 year experience. Transplant Proc 1995: 27 ( I ): 1351 -(<
163. Abu-Elmagd K, T/akis A. Todo S. Monitoring and treatment of intestinal allograft rejection in humans. Transplant Proc 1993: 25 (1 Book II): 1202-3
164. Ftirukavva H. Mane/ R. Kusne S. et al. Cytomegalo virus disease in intestinal transplantation. Transplant Proc 1995; 27 ( 11: 1357-8
165. Jain AB. Venkataramanan R. Lever J. et al. FK506 in small bowel transplant recipients: pharmacokitietics and dosing. Transplant Proc 1994:26(3): 1609-10
166. Bismuth H. European FK 506 Multicenter Liver Study Group. Comparison of FK 506- and cyclosporine based immunosup pression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety protile. Transplant Proc 1995: 27 ( I ): 45-9
167. Gjertson DW. Cecka JM. Tera.saki PI. The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation 1995:60(12): 1384-8
168. Lewis WD, Jenkins RL, Burke PA. FK506 rescue therapy in liver transplant recipients with drug-resistant rejection. Transplant Proc 1991; 23 (6): 2989-91
169. Rucay P. Samuel D, Gillet D, el al. FK506 rescue therapy for refractory acute rejection in five liver recipients. Transplant Proc 1991; 23 (6): 3000-1
170. Platz K-P, Mueller AR, Zytowski M, et al. OKT3 vs FK506 rescue management of acute steroid-resistant and chronic rejection. Transplant Proc 1995:27(1): 1111-3
171. Opelz G. Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome. Transplantation 1994: 58 (4): 443-6
172. Griffin PJA, Gomes DaCosta CA, Salaman JR. Renal transplantation without steroids: a controlled clinical trial. Transplant Proc 1986; 18 (4): 797-8
173. Tarantimo A, Aroldi A, Stucchi L, et al. A randomized prospective trial comparing cyclosporine monotherapy with tripledrug therapy in renal transplantation. Transplantation 1991; 52(0:53-7
174. Johnson RWG, Mallick NP, Bakran A, etal. Cadaver renal transplantation without maintenance steroids. Transplant Proc 1989; 21 (1): 1581-2
175. Jain AB, Fung JJ, Tzakis AG, et al. Comparative study of cyclosporine and FK506 dosage requirement in adults and pédiatrie orthotopic liver transplantation. Transplant Proc 1991; 23 (6): 2763-6
176. Neuhaus P. McMaster P. Calne R, et al. Oral taerolimus (FK506) therapy in the immediate postoperative period eliminates the need for intravenous administration following liver transplantation [abstract|. London: Third Congress of the International Liver Transplantation Society London, 1995 Sep: F1-35
177. Burckart G, Starzl T, Williams L, et al. Cyclosporine monitoring and pharmacokinetics in pédiatrie liver transplant patients. Transplant Proc 1985; 17: 1172-5
178. Burckart GJ, Venkataramanan R, Ptachcinski RJ, et al. Cyclosporine absorption following orthotopic liver transplantation. J Clin Pharmacol 1986; 26: 647-51
179. Burckart GJ, Venkataramanan R, Zaghloul I, et al. Cyclosporine clearance in children following organ transplantation. J Clin Pharmacol 1984:24:412
180. Jain A, Venkataramanan R, Fung JJ, etal. Comparative study of pharmacokinetic profile following intravenous infusion of taerolimus in pédiatrie and adult liver transplant recipients |abstract|. Hepatology 1995; 22 (4 Pt 2): I43A
181. Jain AB, Abu-Elmagd K, Abdallah H. et al. Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol 1993; 33 (7): 606-11
182. Jain AB, Fung JJ, Todo S, et al. One thousand consecutive primary orthotopic liver transplants under FK506: survival and adverse events. Transplant Proc 1995:27(1): 1099-104
183. Monsour HP, Wood RP, DyerCH, et al. Renal insufficiency and hypertension as long-term complications in liver transplantation. Semin Liver Dis 1995; 15 (2): 123-32
184. Backman L, Nicar M, Levy M, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Transplantation 1994; 57 (4): 519-25
185. Shaw LM, Yatscoff RW, Bowers LD, et al. Canadian consensus meeting on cyclosporin monitoring: report of consensus panel. Clin Chem 1990:36(10): 1841-6
186. Todo S, Fung JJ, Starzl TE, et al. Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg 1990; 212: 295-305
187. Mueller AR, Platz KP, Sechstem WO, et al. Neurotoxicity after orthotopic liver transplantation. A comparison be-tween cyelosporine and FK506. Transplantation 1994; 58 (2): 155-70
188. Eidelman BH, Abu-Elmagd K, Wilson J, et al. Neurological complications of FK506. Transplant Proc 1991; 23 (6): 3175-8
189. Reyes J. Gayowski T. Fung J. et al. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. Transplantation 1990; 50 (6): 1043-5
190. Porayko MK. Gonwa TA. Klintmalm GB, et al. US Multicenter Liver Study Group. Comparing nephrotoxicity ot'FK 506 and cyelosporine regimens after liver transplantation: preliminary results from US Multicenter Trial. Transplant Proc 1995; 27 (1); 1114-6
191. McDiarmid SV. Colonna II JO, Shaked A. et al. A comparison of renal function in cyelosporine- and FK-506-treated patients after primary orthotopic liver transplantation. Transplantation 1993; 56 (4): 847-53
192. Platz KP, Mueller AR. Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyelosporine and FK506. Transplantation 1994; 58 (2): 170-8
193. McCauley J, Takaya S, Fung J, et al. The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc 1991;23: 1444-7
194. Randhawa P. Shapiro R, Jordan M. et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506: clinical significance and comparison. Am J Surg Pathol 1993; 17: 60-8
195. McCauley J. The nephrotoxicity of FK506 as compared with cyclosporin. CurrOpin Nephrol Hypertens 1993; 2: 662-9
196. McCauley J. Fung J, Todo S, et al. Changes in renal function after liver transplantation under FK506. Transplant Proc 1991; 23 (6): 3143-5
197. Thompson CB. Sullivan KM, June CH, et al. Association between cyclosporin neurotoxicily and hypomagnesaemia. Lancet 1984; II: 1116-20
198. Tzakis AG. Reyes J. Todo S. et al. FK 506 versus cyelosporine in
199. Egawa H, Esquivel CO, So SK, et al. FK506 conversion therapy in pédiatrie liver transplantation. Transplantation 1994; 57 (8): 1169-73
200. Kretz AJ, Dmitrewski J. Mayer D. et al. Postoperative glucose metabolism in liver transplant recipients. A two-year prospective randomized study of eyclosporine versus FK506. Transplantation 1994; 57 (11): I666-9
201. Steinmutter TA, Graf KJ, Schleicher J, et al. The effect of FK506 versus cyelosporine on glucose and lipid metabolism - a randomized trial. Transplantation 1994; 54: 669-74
202. Aboulijoud MS, Levy MF, Glintmalm GB, and the US Multicenter Study Group. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter trial. Transplant Proc 1995:27(1): 1121-3
203. Senninger N, Golling M, Datsis, K, et al. Glucose metabolism following liver transplantation and immunosuppression with cyelosporine A or FK 506. Transplant Proc 1995; 27 ( I ): 1127-8
204. Ballantyne CM, Radovancevic B, Farmer JA, et al. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol 1992: 19: 1315-21
205. Kusne S, Fung J. Alessiani M. et al. Infection during a randomized trial comparing cyelosporine to FK506 immunosup-pression in liver iransplaniation. Transplant Proc IW2: 24: 429-30
206. Hadlcy S, Suniore MH. Lewis WD. el al. Major infectious complications at'ler orthotopic liver transplantation and comparison ot outcomes in patients receiving cyclosporine or FK506 as primary immunosupprcssion. Transplantation 1995: 59: 5 I -9
207. Nalesnik MA. Ja He R. Star/I TE. et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting ol cyclosporine A-prcdnisone immunosuppression. Am J Pathol I9XX: 13.1: 173-92
208. X. Nalesnik M. Locker J, Jaffe R. et al. Experience with post transplant lymphoproliferativc disorders in solid organ transplant recipients. Clin Transpl 1992:6:249-52
209. Cox K. Lawrence L. Garcia-Kennedy R. el ul. An increased incidence of Epstein-Barr \irus infection and lymphoproliterative disease in voung children on FK 506 after liver transplantation. Transplantation 1995: 59 (4): 524-9
210. Atkinson P. Jouhert G. Barron A. et al. Hypertrophie cardiomyopathv associated with tacrolhmis in paediatric transplant patients. Lancet 1995: 345: 894-6